Sanofi completes acquisition of Inhibrx, Inc. to enhance rare disease pipeline
05/30/24, 1:13 PM
Location
paris
san diegoIndustry
pharmaceutical
medical
biotechnology
health care
biotechnology
biopharma
therapeutics
Sanofi has successfully completed its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, aiming to provide better treatment options for AATD patients and strengthen Sanofi’s capabilities in the healthcare sector.
Company Info
Location
Paris, Ile-de-France, France
Company info
LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Holdings plc (Gyroscope), a clinical-stage gene therapy company focused on diseases of the eye, today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44.5 million) in equity in Gyroscope.
Related People
New Feature: Generate AI-Powered Emails Instantly!
Use one of the following options:
- Click the AI button next to your contact's email to generate a draft automatically.
- Use Copy to Clipboard to paste the email into your favorite email service.
- Click Send via Webmail to use Gmail or another online client.
Important: If nothing happens when you click, you might not have a default email client set up.